These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20479099)

  • 1. Histone deacetylase inhibitors: Are they here to stay?
    Ibrahim RB
    Am J Health Syst Pharm; 2010 May; 67(10):791. PubMed ID: 20479099
    [No Abstract]   [Full Text] [Related]  

  • 2. Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity.
    Warlick ED; Cao Q; Miller J
    Leukemia; 2013 Aug; 27(8):1789-91. PubMed ID: 23446311
    [No Abstract]   [Full Text] [Related]  

  • 3. Vorinostat approved for rare lymphoma.
    Thompson CA
    Am J Health Syst Pharm; 2006 Nov; 63(22):2168. PubMed ID: 17090730
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II trial of vorinostat in advanced melanoma.
    Haas NB; Quirt I; Hotte S; McWhirter E; Polintan R; Litwin S; Adams PD; McBryan T; Wang L; Martin LP; vonMehren M; Alpaugh RK; Zweibel J; Oza A
    Invest New Drugs; 2014 Jun; 32(3):526-34. PubMed ID: 24464266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
    Prebet T; Vey N
    Expert Opin Investig Drugs; 2011 Feb; 20(2):287-95. PubMed ID: 21192773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vorinostat (Zolinza) for cutaneous T-Cell lymphoma.
    Med Lett Drugs Ther; 2007 Mar; 49(1256):23-4. PubMed ID: 17351559
    [No Abstract]   [Full Text] [Related]  

  • 8. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma.
    Kavanaugh SM; White LA; Kolesar JM
    Am J Health Syst Pharm; 2010 May; 67(10):793-7. PubMed ID: 20479100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy.
    Kalanxhi E; Risberg K; Barua IS; Dueland S; Waagene S; Andersen SN; Pettersen SJ; Lindvall JM; Redalen KR; Flatmark K; Ree AH
    Cancer Res Treat; 2017 Apr; 49(2):374-386. PubMed ID: 27488871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vorinostat for refractory or relapsing epidermotropic T-cell lymphoma: a retrospective cohort study of 15 patients.
    Kogge A; Volteau C; Saint-Jean M; Peuvrel L; Brocard A; Knol AC; Renaut JJ; Dréno B; Quéreux G
    Acta Derm Venereol; 2015 Jan; 95(1):72-7. PubMed ID: 24806744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer drug shows promise against lupus.
    Foubister V
    Drug Discov Today; 2003 Apr; 8(8):333-4. PubMed ID: 12681930
    [No Abstract]   [Full Text] [Related]  

  • 12. [Vorinostat in the treatment of cutaneous T-cell lymphomas. Treatment with histone deacetylases inhibitors].
    Zirlik K; Nashan D; Veelken H
    Pharm Unserer Zeit; 2010 May; 39(3):190-6. PubMed ID: 20425773
    [No Abstract]   [Full Text] [Related]  

  • 13. The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome.
    Sanli H; Akay BN; Anadolu R; Ozcan M; Saral S; Akyol A
    J Drugs Dermatol; 2011 Apr; 10(4):403-8. PubMed ID: 21455551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.
    Munster PN; Thurn KT; Thomas S; Raha P; Lacevic M; Miller A; Melisko M; Ismail-Khan R; Rugo H; Moasser M; Minton SE
    Br J Cancer; 2011 Jun; 104(12):1828-35. PubMed ID: 21559012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy.
    Garcia-Manero G
    Best Pract Res Clin Haematol; 2012 Dec; 25(4):427-35. PubMed ID: 23200539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
    Duvic M
    Dermatol Clin; 2015 Oct; 33(4):757-64. PubMed ID: 26433847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.
    Richardson PG; Harvey RD; Laubach JP; Moreau P; Lonial S; San-Miguel JF
    Expert Rev Clin Pharmacol; 2016; 9(1):35-48. PubMed ID: 26503877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.
    Tambo Y; Hosomi Y; Sakai H; Nogami N; Atagi S; Sasaki Y; Kato T; Takahashi T; Seto T; Maemondo M; Nokihara H; Koyama R; Nakagawa K; Kawaguchi T; Okamura Y; Nakamura O; Nishio M; Tamura T
    Invest New Drugs; 2017 Apr; 35(2):217-226. PubMed ID: 28138828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of cutaneous T-cell lymphoma: focus on vorinostat.
    Heymann WR
    J Am Acad Dermatol; 2008 Oct; 59(4):696-7. PubMed ID: 18793938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology.
    Shah RR
    Drug Saf; 2019 Feb; 42(2):235-245. PubMed ID: 30649740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.